1. Home
  2. NCPL vs CDT Comparison

NCPL vs CDT Comparison

Compare NCPL & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCPL

Netcapital Inc.

HOLD

Current Price

$0.56

Market Cap

7.1M

Sector

Finance

ML Signal

HOLD

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.62

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCPL
CDT
Founded
1984
2019
Country
United States
United States
Employees
20
4
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
5.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCPL
CDT
Price
$0.56
$0.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
647.1K
14.4M
Earning Date
03-19-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$739.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.37
52 Week High
$8.75
$11.00

Technical Indicators

Market Signals
Indicator
NCPL
CDT
Relative Strength Index (RSI) 42.42 38.54
Support Level $0.35 $0.51
Resistance Level $0.60 $0.73
Average True Range (ATR) 0.09 0.23
MACD -0.05 0.06
Stochastic Oscillator 13.95 4.67

Price Performance

Historical Comparison
NCPL
CDT

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: